semaglutide and autoimmune GLP-1 Agonists in Disease autoimmune disease and semaglutide Disease:

Trial Metric Retatrutide 12mg (TRIUMPH-4) Semaglutide 2.4mg (STEP 1) Mean Weight Loss 28.7% at 68 weeks 14.9% at 68 weeks Mechanism Triple agonist (GLP-1/GIP/GCGR) Single agonist (GLP-1) FDA Status Phase 3 (investigational) Approved (Wegovy) Dosing Weekly subcutaneous Weekly subcutaneous Common Adverse Events GI (nausea, vomiting, diarrhea), dysesthesia GI (nausea, vomiting, diarrhea) Important caveat: These results come from different trial populations and study designs

however, we believe that strict inclusion criteria including first-year compliance, serum availability for pharmacokinetic measurements and a reasonable follow-up time are integral to CYP2D6-related outcome analysis

Alpha Lipoic Acid rejuvenates the skin by enhancing its texture and may reduce the visibility of age-related signs

A balanced diet supports healthier skin overall